Empagliflozin’s role in reducing ventricular repolarization heterogeneity: insights into cardiovascular mortality decline from the EMPATHY-HEART trial
Authors' conclusion
The EMPATHY-HEART trial preliminarily suggests that empagliflozin decreases heterogeneity in ventricular repolarization among patients with T2DM and CHD. This reduction in TWH may provide insight into the mechanism behind the decreased cardiovascular mortality observed in previous trials, potentially offering a therapeutic pathway to mitigate the risk of severe arrhythmias in this population.
Study context
- Population
- Adult outpatients with T2D and coronary heart disease with T-wave heterogeneity (TWH) > 80 µV at baselinehigh CV risk enrolment
- Participants
- 90 outpatients
- Comparison
- Empagliflozin 25 mg daily, baseline vs 4 weeks
- Outcome
- Significant (p < 0.05) change in T-wave heterogeneity (TWH)
- Follow-up
- 4 weeks
Main finding
As reported in the abstract
Mean TWH · baseline to 4 weeks
- Mean TWH reduced from 116 to 103 µV (p = 0.01)
Further findings
- Empagliflozin adherence
- exceeded 80%
- Notable reductions in blood pressure without affecting heart rate
Safety
- Level 1 hypoglycaemia
- 13.3%
- Side effects generally mild; infrequent urinary and genital infections
Original publication
Empagliflozin’s role in reducing ventricular repolarization heterogeneity: insights into cardiovascular mortality decline from the EMPATHY-HEART trial. Cardiovasc Diabetol. Published 26 June 2024. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →